ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2

ExpreS2ion Biotech Holding AB — Q3 2026 Earnings Presentation

24 slides from ExpreS2ion Biotech Holding AB's earnings presentation, Nov 12, 2026

  1. Slide 1: Innovative immunotherapies for a healthier world

    Interim Report Q3 Webcast 12 November 2026 Innovative immunotherapies for a healthier world Hosted by Nasdaq First North: EXPRS2 ExpreS2ion Biotech Holding AB Company reg. no. 559033 - 3729

  2. Slide 2: Forward-looking statements and disclaimer

    Forward - looking statements and disclaimer Important information This report contains forward - looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar ex pressions identify forward - looking statements. All statements other than statements of historical fac

  3. Slide 3: Three reasons to look at ExpreS2ion now

    Three reasons to look at ExpreS2ion now Product specific Market specific Progress specific 12 of 13 ~3 in 10 Q1 2027 evaluable patients made HER2 first- line HER2 - positive patients Phase I primary readout: key data to antibodies in the Phase I trial of experience disease progression or support par

  4. Slide 4: One oncology lead asset, with partner-funded infectious disease programmes

    One oncology lead asset, with partner - funded infectious disease programmes Target Pre - clinical Disease Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platform COVID - 191 ABNCoV2/RBD - VLP ExpreS2 + VLP Malaria: RH5.1 Licensed to SII Blo

  5. Slide 5: ExpreS2: Platform and partnered programmes

    ExpreS2 Platform and partnered programmes

  6. Slide 6: ExpreS2: a platform validated in Phase III

    ExpreS2: a platform validated in Phase III 500+ 4,205 >400 mg proteins and VLPs expressed since 2010; participants in the COVID - 19 clinical Phase III of RH5.1 malaria antigen from one 25 - litre >90% success rate study , which met its primary endpoint cGMP batch 1 Platform income and funding Techn

  7. Slide 7: Malaria: our licensed antigens advanced in Q3, with data due in Q1 2027

    Malaria: our licensed antigens advanced in Q3, with data due in Q1 2027 Q3 2026 Next Licensed to SII Phase Ib/II concluded Phase IIb completes Q4 2026 RH5.1 + R78C 2 new trials with R21 Data Q1 2027 Phase IIb concluded 24- month Phase IIb data RH5.1 New adjuvant trial planned Q1 2027 Oxford rights D

  8. Slide 8: Nipah vaccine is heading for the clinic, grant-funded to Phase I

    Nipah vaccine is heading for the clinic, grant - funded to Phase I 25 years of recurring Nipah outbreaks Q3 2026 GMP - ready antigen process being finalised GMP manufacturing under way at Northway Biotech West Bengal 2001, 2007, 2026 Next Toxicology study → clinical trial application → Phase I/IIa,

  9. Slide 9: ES2B-C001: Targeting HER2-expressing cancers

    ES2B - C001 Targeting HER2 - expressing cancers

  10. Slide 10: ADCs raised the bar, but durability remains the unmet need

    ADCs raised the bar, but durability remains the unmet need Median PFS, first - line HER2+ mBC Progression or deceased within 24 months Cross - trial view of the progress made and the gap that remains ~3 in 10 First- line T - DXd + pertuzumab ¹ 40.7 mo Long - term 18.5 mo disease control CLEOPATRA DE

  11. Slide 11: ES2B-C001 targets all four HER2 domains to build durable immunity

    ES2B - C001 targets all four HER2 domains to build durable immunity ES2B - C001 construct HER2 protein All 4 extracellular HER2 domains ExpreS2 platform presents full ExpreS2 platform extracellular HER2 domain Designed to enable antibody responses against all 4 HER2 domains v. SoC mAbs that target a

  12. Slide 12: Phase I: anti-HER2 antibody responses in evaluable patients

    Phase I: anti - HER2 antibody responses in 12 of 13 evaluable patients Anti - HER2 antibody titres The trial Rise with each dose, then decline gradually Design Open - label Phase I dose escalation 9,600 Population geometric mean titre Advanced HER2+ or HER2 - low breast cancer 4,800 Anti- HER2 Ig λ

  13. Slide 13: Phase I reads out in Q1 2027; Phase II targets first line breast cancer

    Phase I reads out in Q1 2027; Phase II targets first - line breast cancer Q4 2026 Phase I priming phase completes (last patient’s last visit, December) Phase II at a glance End - 2026 Population Translational results First- line HER2 - positive metastatic breast cancer Scope Q1 2027 80 – 120 patient

  14. Slide 14: Q3 & Nine-Month 2026 Results

    expreSeion BIOTECH Q3 & Nine- Month 2026 Results

  15. Slide 15: Q3 2026 Financial Highlights

    Q3 2026 Financial Highlights Operating income Operating loss Net loss mSEK 2.3 m SEK 12.8 mSEK 9.9 flat vs Q3 2025 +31% vs Q3 2025 +18% vs Q3 2025 TO 13 proceeds R&D spend Cash at 30 September mSEK 19.3 1 mSEK 3.7 mSEK 24.0 Before transaction costs +56% vs Q3 2025 1 Includes proceeds from TO 13 warr

  16. Slide 16: Income Flat YoY

    Income Flat YoY SEK ‘000s Operating income Net sales (CRO) Other operating income (Grants) 12,000 4,000 10,000 Net sales Other operating income Grant income includes VICI - Disease 9,000 3,000 7,500 subcontracting, offset in R&D costs 6,000 2,000 5,000 1,364 Flat YoY 2,292 +286% - 52% 3,000 1,000 2,

  17. Slide 17: Costs up 25% YoY, Well Down on Q2

    C osts up 25% YoY, W ell D own on Q2 SEK ‘000s Operating expense R&D costs (external) 0 0 -3,000 -6,000 - 3,742 -5,000 -9,000 -12,000 R&D +56% YoY: ES2B - C001 clinical trial costs and higher CMC costs -10,000 -15,000 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 Personnel costs -15,000 +25% 0 Y

  18. Slide 18: Cost Structure by Activity

    Cost Structure by Activity In 2026, ExpreS2ion has spent a relative larger proportion of costs on the Nipah virus project as it progressed towards cGMP manufacturing – largely funded by the VICI - Disease grant 9M 2025: SEK 42.8m 9M 2026: SEK 57.4m Admin. / Admin. / listing costs listing costs ES2B

  19. Slide 19: Net Result For The Period

    Net Result For The Period SEK ‘000s Q3 profit / loss YTD 2026 profit / loss YTD profit / loss 0 0 -3,000 -10,000 -6,000 +18% -20,000 YoY - 2% -9,000 - 8,445 -30,000 YoY - 29,910 - 29,226 - 9,935 -12,000 -40,000 2025 2026 2025 2026 Q3 2025 → Q3 2026: drivers of change YTD 2025 → YTD 2026: drivers of

  20. Slide 20: Cash Development

    Cash Development SEK millions 60 +11.1 47.6 45 - 1.1 36.9 +0.7 +24.9 +0.5 34.4 - 0.3 30 +0.2 +0.0 +0.5 24.0 +0.1 21.8 - 25.5 - 0.1 - 11.1 15 - 12.5 0 09/25 OpCF FinCF FX 12/25 OpCF FinCF FX 03/26 OpCF FinCF InvCF FX 06/26 OpCF FinCF InvCF FX 09/26 20

  21. Slide 21: Cash Balance & Key Drivers (1Q24 – 3Q26)

    Cash Balance & Key Drivers (1Q24 – 3Q26) SEK millions • Q3 2026 cash: mSEK 24.0 100 TO 10 • TO 13 and directed issue: mSEK 19.3 Rights Warrants gross, mostly received October 2026 Issue 82 80 Dividend 76 • Alumni Capital put option: up to 69 mSEK 50 over 24 months from 2027; Grant 60 drawdown notice

  22. Slide 22: From Phase I readout to potential partnering: the year ahead for ES2B-C001

    From Phase I readout to potential partnering: the year ahead for ES2B - C001 Q 1202 7 Q 2 2027 Q 3 2027 Beyond Phase I primary readout, ES2B - C001 incl. preliminary antitumour Phase II design decision; potential partnering Out - licensing / Phase II Breast cancer activity (RECIST); potential partne

  23. Slide 23: Q&A Questions from the audience

    Q&A Questions from the audience investor@expres2ionbio.com investor.expres2ionbio.com Bent U. Frandsen, CEO · Keith Alexander, CFO

  24. Slide 24: ExpreS2ion Biotech Holding AB

    ExpreS2ion Biotech Holding AB Innovative immunotherapies for a healthier world c/o Mindpark Rönnowsgatan 8c S - 252 25 Helsingborg www.expres2ionbio.com ExpreS2ion Biotech Holding AB Innovative immunotherapies for a healthier world c/o Mindpark Rönnowsgatan 8c www.expres2ionbio.com S - 252 25 Helsin

ExpreS2ion Biotech Holding — Q3 2026 Earnings Presentation on 6ix